PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12444236

Triptans.

Scott C Armstrong·Kelly L Cozza
View original source ↗Export metadata ↓

Abstract

Triptans are potent serotonin (5-HT) 1B/1D receptor agonists used to abort and treat migraine headaches. Although the triptans share pharmacodynamic characteristics at 5-HT(1B/1D) receptors, they differ pharmacokinetically. This column reviews how the triptans are metabolized. Generally, the triptans are metabolized by phase I monoamine oxidases (MAOs) and by various cytochrome p450 enzymes. However, each triptan has a unique metabolic profile, leading to significant differences in each triptan's potential for drug-drug interactions. These differences are detailed in this review.

Explore related subjects

Drug InteractionsHumansMigraine DisordersSerotonin Receptor AgonistsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Scott C Armstrong, Kelly L Cozza. Triptans.. https://doi.org/10.1176/appi.psy.43.6.502

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

The interaction of metal ions and Marimastat with matrix metalloproteinase 9.

The effect of a range of metal ions on the ability of Marimastat to inhibit matrix metalloproteinase 9 (MMP-9) was examined in a fluorescence based proteolytic assay. Whilst none of the metals examined significantly affected the inhibitory ability of Marimastat, several metal ions did have a significant effect on MMP-9 activity itself. In the absence of Marimastat, Zn(II) and Fe(II) significantly inhibited MMP-9 activity at metal ion concentrations of 10 and 100 microM, respectively. In both the absence and presence of Marimastat, Cd(II) significantly inhibited MMP-9 at 100 microM. In contrast, 1 mM Co(II) significantly upregulated MMP-9 proteolytic activity.

Drug Interactions↗